Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL

NCT03707847 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

ALK-Positive Anaplastic Large Cell Lymphoma

Interventions

DRUG: Crizotinib
DRUG: Etoposide Capsule
PROCEDURE: Auto-HSCT

Sponsor

Mingzhi Zhang